An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Major Depressive Disorder.

Trial Profile

An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Escitalopram (Primary) ; SSR 149415 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2009 Actual patient number (319) added as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 14 Feb 2008 Status change from in progress to completed, as reported by clilnicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top